Management of Hematochezia After Chemotherapy

Initial Assessment

The American Society of Clinical Oncology recommends obtaining a detailed history of onset and duration of bleeding in relation to chemotherapy administration, including documenting the number of stools and stool composition, to assess the severity of hematochezia 3
Patients should be assessed for fever, dizziness, abdominal pain/cramping, or weakness to rule out sepsis, bowel obstruction, and dehydration, with a comprehensive review of their medication profile to identify potential causative agents 3

A comprehensive stool workup, including testing for infectious causes, should be performed to determine the underlying cause of hematochezia, with a complete blood count to assess for anemia and neutropenia 3, 4
Early endoscopic evaluation by experienced endoscopists is crucial for diagnosis and potential intervention, with consideration of platelet support availability before endoscopic procedures in patients with thrombocytopenia 1, 2, 5

Chemotherapy-induced direct mucosal injury, particularly from taxanes and bevacizumab, is a common cause of hematochezia, with infectious causes, such as C. difficile and CMV, also being potential underlying causes 2, 5
Neutropenic enterocolitis/typhlitis and ischemic colitis are also possible causes of hematochezia after chemotherapy, with radiation-induced telangiectasia being a consideration in patients with a history of pelvic radiotherapy 1, 2, 6

For mild to moderate bleeding, dietary modifications, such as eliminating lactose-containing products and high-osmolar supplements, and encouraging clear liquids, may be implemented, with consideration of temporary interruption of chemotherapy until symptoms resolve 3, 2
For severe bleeding, hospitalization or intensive outpatient management, administration of octreotide, and start of intravenous fluids and broad-spectrum antibiotics may be necessary, with early endoscopic therapy for localized bleeding sites 3, 1, 2, 5

Neutropenic enterocolitis/typhlitis requires bowel rest, IV fluids, parenteral nutrition, broad-spectrum antibiotics, and normalization of neutrophil counts, with colonoscopy being contraindicated due to high perforation risk 1, 2
Chemotherapy-associated bowel syndrome significantly increases the risk of ICU transfer and death, highlighting the need for prompt recognition and management 2

Continued monitoring of stool frequency, consistency, and presence of blood, as well as reassessment of hydration status and electrolyte balance, is essential, with resumption of chemotherapy at a reduced dose only after complete resolution of symptoms 3, 4

Endoscopic biopsy can be hazardous in patients with thrombocytopenia or previous radiotherapy, and chemotherapy-induced platelet dysfunction may affect hemostasis even with adequate platelet counts, highlighting the need for caution in these patients 2
Argon plasma coagulation for radiation proctopathy should be used with extreme caution due to high complication rates, and patients may be reluctant to discuss symptoms, requiring vigilance from healthcare providers 6